PURPOSE: To evaluate the impact of HCV (hepatitis C virus) and HBV (hepatitis B virus) infection on long-term graft and patient survival in renal transplantation. METHODS: One hundred and nine kidney allograft recipients were evaluated regarding the presence of antibodies against HCV and hepatitis B surface antigen. Patients were divided into four groups according to their serologic status and followed for ten years for survival analysis. Age, gender, renal failure etiology, length of previous dialysis and post transplantation periods were evaluated. RESULTS: Length on dialysis time was significantly longer in the anti-HCV positive group. There was also a higher number of patients with re-transplants in the HBV and HCV groups. There were no significant differences in 10-year patient survival in the anti-HCV positive group (71.0%; relative risk: 1.13; CI: 0.86 - 1.47) and in the HBV infected group (77.8%; relative risk: 1.03; CI: 0.7 - 1.5) compared to the not infected group (80%). However, the group of patients infected with both viruses presented a significantly lower 10-year patient survival (37.5%; relative risk: 2,13; CI: 0,86 - 5,28) compared to the index group. There were no significant differences on graft survival among the groups. CONCLUSION: In the present study renal transplant patients infected concomitantly with HBV and HCV present a significantly lower long-term patient survival.
Renal Transplantation; Hepatitis B; Hepatitis C
